<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02977494</url>
  </required_header>
  <id_info>
    <org_study_id>2016-000433-51</org_study_id>
    <nct_id>NCT02977494</nct_id>
  </id_info>
  <brief_title>Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment</brief_title>
  <acronym>GMMG-DANTE</acronym>
  <official_title>Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myeloma patients with renal impairment need a rapid and effective reduction of tumor burden&#xD;
      to enable renal recovery, which is correlated with prognosis of the patients. However,&#xD;
      effective combination regimens are often hampered by necessary dose reductions or increased&#xD;
      toxicity in renally impaired patients. The well known positive effects on renal impairment by&#xD;
      Bortezomib combined with Daratumumab, which, as all monoclonal Antibody, is not renally&#xD;
      excreted or metabolized and as so far known should not add significant toxicity but efficacy,&#xD;
      makes the proposed combination of Daratumumab, Bortezomib and Dexamethasone highly attractive&#xD;
      for renally impaired MM patients.&#xD;
&#xD;
      In the current clinical trials with Daratumumab patients with renal function impairment (GFR&#xD;
      ≤ 20 ml/min) were so far excluded. Consequently questions about efficacy, safety and&#xD;
      pharmacokinetics of Daratumumab in combination with Bortezomib and Dexamethasone in patients&#xD;
      with relapsed and refractory MM and severe renal impairment are still unanswered. This trial&#xD;
      will answer these questions for a patient group, who has still an unmet need for novel and&#xD;
      effective treatment options&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy (overall response rate, ORR according to IMWG recommendations) of the combination of daratumumab, bortezomib and dexamethasone in subjects with relapsed and refractory MM and impaired renal function</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Daratumumab Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38</description>
    <arm_group_label>Daratumumab Bortezomib</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>Daratumumab Bortezomib</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Daratumumab Bortezomib</arm_group_label>
    <other_name>Fortecortin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be at least 18 years of age&#xD;
&#xD;
          2. Written informed consent&#xD;
&#xD;
          3. Subjects must have had documented multiple myeloma requiring treatment as defined by&#xD;
             the criteria below:&#xD;
&#xD;
             Monoclonal plasma cells in the bone marrow &gt; 10% and/or presence of a biopsy-proven&#xD;
             plasmacytoma at some point in their disease history requiring treatment according&#xD;
             diagnostic criteria (IMWG updated criteria 2014, Rajkumar et al. 2014) see appendix I&#xD;
             With measurable disease at screening (serum M-protein &gt; 500 mg/dl or urine M-protein &gt;&#xD;
             200 mg/24h, in case of oligosecretory MM serum free light chain &gt; 10 mg/dl and&#xD;
             abnormal kappa/lambda free light chain ratio)&#xD;
&#xD;
          4. GFR &lt; 30 ml/min and /or subjects undergoing hemodialysis&#xD;
&#xD;
          5. Subject must have received at least 1 prior treatment line&#xD;
&#xD;
          6. Subjects must have documented evidence of progressive disease after the last treatment&#xD;
             line&#xD;
&#xD;
          7. ECOG performance status 0-3 (ECOG 3 is only allowed if due to myeloma disease)&#xD;
&#xD;
          8. Subjects must have certain pretreatment laboratory values meeting the following&#xD;
             criteria during the Screening Phase:&#xD;
&#xD;
               1. Hemoglobin ≥7.5 g/dl (4,66 mmol/L; prior red blood cells (RBC) transfusion or&#xD;
                  recombinant human erythropoietin use is permitted).&#xD;
&#xD;
               2. Absolute neutrophil count ≥ 1.0 x109/L (granulocyte colony stimulating factor&#xD;
                  (GCSF) use is permitted);&#xD;
&#xD;
               3. Platelet count more or equal 70 x109/L for subjects in whom ˂ 50% of bone marrow&#xD;
                  nucleated cells are plasma cells; otherwise platelet count ˃ 50 x 109/L&#xD;
                  (transfusions are not permitted to achieve this minimum platelet count ),&#xD;
&#xD;
               4. Aspartate aminotransferase (AST) ≤ 2,5 x upper limit of normal (ULN);&#xD;
&#xD;
               5. Alanine aminotransferase (ALT) ≤ 2,5 x ULN&#xD;
&#xD;
               6. Total bilirubin ≤ 2.0 x ULN ,except in subjects with congenital bilirubinemia,&#xD;
                  such as Gilbert syndrome (direct bilirubin ≤ 2.0 x ULN&#xD;
&#xD;
               7. Corrected serum calcium ≤ 14 mg/dl (≤3,5mmol/L); or free ionized calcium ˂ 6,5&#xD;
                  mg/dL(˂1,6 mmol/L)&#xD;
&#xD;
          9. Women of childbearing potential must commit to either abstain continuously from&#xD;
             heterosexual sexual intercourse or to use 2 methods of reliable birth control&#xD;
             simultaneously. This includes one highly effective form of contraception (tubal&#xD;
             ligation, intrauterine device [IUD], hormonal [birth control pills, injections,&#xD;
             hormonal patches, vaginal rings or implants] or partner's vasectomy) and one&#xD;
             additional effective contraceptive method (male latex or synthetic condom, diaphragm,&#xD;
             or cervical cap). Contraception must begin 4 weeks prior to dosing. Reliable&#xD;
             contraception is indicated even where there has been a history of infertility, unless&#xD;
             due to hysterectomy.&#xD;
&#xD;
         10. A woman of childbearing potential must have a negative urine or serum pregnancy test&#xD;
             at screening within 14 days prior to treatment start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has received prior Daratumumab or other Anti-CD38 antibodies (previous&#xD;
             treatment with Elotuzumab is allowed)&#xD;
&#xD;
          2. Evidence of intolerance to bortezomib or known allergies, hypersensitivity or&#xD;
             intolerance to monoclonal antibodies&#xD;
&#xD;
          3. Subject has received anti-myeloma treatment within 2 weeks of Cycle 1, day 1. The only&#xD;
             exception is emergency use of a short course of corticosteroids (equivalent of&#xD;
             Dexamethasone 40 mg/day for a maximum of 4 days) before treatment.&#xD;
&#xD;
          4. Active graft-versus host disease under immunosuppressive treatment&#xD;
&#xD;
          5. Subject is a woman who is pregnant or breastfeeding&#xD;
&#xD;
          6. Prior invasive malignancy within 5 years before trial inclusion&#xD;
&#xD;
          7. Active, uncontrolled infection.&#xD;
&#xD;
          8. Subject has peripheral neuropathy ≥ 3 or neuropathic pain Grade 2 or higher&#xD;
&#xD;
          9. Subject has either of the following:&#xD;
&#xD;
               1. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory&#xD;
                  volume in 1 second (FEV1) &lt;50% of predicted normal. Note that FEV1 testing is&#xD;
                  only required for subjects suspected of having COPD&#xD;
&#xD;
               2. Known moderate or severe persistent asthma, or currently has uncontrolled asthma&#xD;
                  of any classification. (Note that subjects who currently have controlled&#xD;
                  intermittent asthma or controlled mild persistent asthma are allowed to&#xD;
                  participate in the study).&#xD;
&#xD;
         10. Subject has clinically significant cardiac disease, including myocardial infarction&#xD;
             within 6 months before date of study entry, unstable angina, cardiac insufficiency New&#xD;
             York Heart Association (NYHA) Class III-IV or uncontrolled arrhythmia&#xD;
&#xD;
         11. Subject has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined&#xD;
             significance, or smoldering multiple myeloma. Monoclonal gammopathy of undetermined&#xD;
             significant is defined by presence of serum M-protein ˂ 3 g/dL; absence of lytic bone&#xD;
             lesions, anemia, hypercalcemia and renal insufficiency related to M-protein; and (if&#xD;
             determined) proportion of plasma cells in the bone marrow of 10% or less (Kyle et al.&#xD;
             2003). Smoldering multiple myeloma is defined as asymptomatic multiple myeloma with&#xD;
             absence of related organ or tissue impairment and organ damage (Kyle et al., 2003,&#xD;
             2007).&#xD;
&#xD;
         12. Subject has a diagnosis of Waldenström's disease, or other conditions in which IgM&#xD;
             M-protein is present in the absence of a clonal plasma cell infiltration with lytic&#xD;
             bone lesions.&#xD;
&#xD;
         13. Subject has had radiation therapy within 14 days of treatment&#xD;
&#xD;
         14. Subject has had plasmapheresis within 14 days of treatment. Screening laboratory&#xD;
             values have to be performed after end of plasmapheresis.&#xD;
&#xD;
         15. Subject is known to be seropositive for human immunodeficiency virus (HIV) or&#xD;
             hepatitis B (defined by a positive test for hepatitis B surface antigen (HBsAg) or&#xD;
             antibodies to hepatitis B surface and core antigen (anti HBs and anti HBc&#xD;
             respectively), or hepatitis C (anti-HCV antibody positive or HCV RNA quantitation&#xD;
             positive).&#xD;
&#xD;
         16. Subject has had major surgery within 2 weeks before treatment und has not fully&#xD;
             recovered from surgery, or has surgery panned during the time the subject is expected&#xD;
             to participate in the study.&#xD;
&#xD;
         17. Incidence of gastrointestinal disease that may significantly alter the absorption of&#xD;
             oral drugs&#xD;
&#xD;
         18. Subject has any concurrent medical or psychiatric condition or disease (eg. active&#xD;
             systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary&#xD;
             disease) that is likely to interfere with the study procedures or results, or that in&#xD;
             the opinion of the investigator, would constitute a hazard for the participating in&#xD;
             this study.&#xD;
&#xD;
         19. Subject has known allergies, hypersensitivity, or intolerance to corticosteroids,&#xD;
             monoclonal antibodies or human proteins, or their excipients (refer to respective&#xD;
             package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived&#xD;
             products.&#xD;
&#xD;
         20. Subject is known or suspected of not being able to comply with the study protocol (eg.&#xD;
             because of alcoholism, drug dependency, or psychological disorder). Subject has any&#xD;
             condition for which, in the opinion of the investigator, participation would not be in&#xD;
             the best interest of the subject (eg, compromise the well-being) or that could&#xD;
             prevent, limit or confound the protocol-specified assessments. Subject is taking any&#xD;
             prohibited medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité Universitätsmedizin BerlinCampus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholische Karl-Leisner Klinikum Goch</name>
      <address>
        <city>Goch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerisity Hospital Muenster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hopsital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>May 27, 2022</last_update_submitted>
  <last_update_submitted_qc>May 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02977494
org study id: 2016-000433-51
nct id: NCT02977494
lead sponsor: 
has dmc: Yes
Myeloma patients with renal impairment need a rapid and effective reduction of tumor burden
      to enable renal recovery, which is correlated with prognosis of the patients. However,
      effective combination regimens are often hampered by necessary dose reductions or increased
      toxicity in renally impaired patients. The well known positive effects on renal impairment by
      Bortezomib combined with Daratumumab, which, as all monoclonal Antibody, is not renally
      excreted or metabolized and as so far known should not add significant toxicity but efficacy,
      makes the proposed combination of Daratumumab, Bortezomib and Dexamethasone highly attractive
      for renally impaired MM patients.

      In the current clinical trials with Daratumumab patients with renal function impairment (GFR
      ≤ 20 ml/min) were so far excluded. Consequently questions about efficacy, safety and
      pharmacokinetics of Daratumumab in combination with Bortezomib and Dexamethasone in patients
      with relapsed and refractory MM and severe renal impairment are still unanswered. This trial
      will answer these questions for a patient group, who has still an unmet need for novel and
      effective treatment options
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Evaluate the efficacy (overall response rate, ORR according to IMWG recommendations) of the combination of daratumumab, bortezomib and dexamethasone in subjects with relapsed and refractory MM and impaired renal function
time frame: two years
arm group label: Daratumumab Bortezomib
arm group type: Experimental
intervention type: Drug
intervention name: Daratumumab
description: Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
arm group label: Daratumumab Bortezomib
other name: Darzalex
intervention type: Drug
intervention name: Bortezomib
arm group label: Daratumumab Bortezomib
other name: Velcade
intervention type: Drug
intervention name: Dexamethasone
arm group label: Daratumumab Bortezomib
other name: Fortecortin
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Germany
country: Greece
responsible party type: Sponsor
mesh term: Multiple Myeloma
mesh term: Neoplasms, Plasma Cell
mesh term: Dexamethasone
mesh term: Dexamethasone acetate
mesh term: Bortezomib
mesh term: Daratumumab
sharing ipd: Undecided